Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

Avalyn Pharma Inc.

Contributing Author

Recent Articles by Avalyn Pharma Inc.

Sep-16	Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors AVLN GlobeNewswire
Sep-08	Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference AVLN GlobeNewswire
Sep-08	Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis AVLN GlobeNewswire
Aug-24	Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 AVLN GlobeNewswire
Aug-12	Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights AVLN +5.41% GlobeNewswire
Jun-17	Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis AVLN GlobeNewswire
Jun-03	Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights AVLN GlobeNewswire
May-27	Avalyn to Participate in the Jefferies Global Healthcare Conference AVLN GlobeNewswire
May-21	Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 AVLN GlobeNewswire
May-05	Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference AVLN -5.64% GlobeNewswire
May-01	Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares AVLN GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)